Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | EML4 - ALK KEAP1 dec exp |
Therapy | Crizotinib |
Indication/Tumor Type | lung cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - ALK KEAP1 dec exp | lung cancer | sensitive | Crizotinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Xalkori (crizotinib) in a lung cancer cell line and patient-derived lung cancer cells harboring EML4-ALK in culture (PMID: 28145866). | 28145866 |
PubMed Id | Reference Title | Details |
---|---|---|
(28145866) | KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. | Full reference... |